Inflammatory marker levels and prediction of patient-reported symptoms in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy

被引：0
|
作者：
Wang, Xin Shelley
Shi, Qiuling
Li, Donghui
Eng, Cathy
Bokhari, Raza H.
Fogelman, David R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e20699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20699
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
    Cartwright, Thomas H.
    Ginsburg, Aimee
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC).
    Banu, E
    Oudard, S
    Banu, A
    Fodor, A
    Landi, B
    Lecomte, T
    Laurent-Puig, P
    Cugnenc, PH
    Andrieu, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 333S - 333S
  • [43] Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy
    Bahra, Marcus
    Pratschke, Johann
    Klein, Fritz
    Neuhaus, Peter
    Boas-Knoop, Sabine
    Puhl, Gero
    Denecke, Timm
    Pullankavumkal, Joyce R.
    Sinn, Marianne
    Riess, Hanno
    Pelzer, Uwe
    PANCREAS, 2015, 44 (06) : 930 - 936
  • [44] A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
    Masashi Kanai
    Kenichi Yoshimura
    Masanori Asada
    Atsushi Imaizumi
    Chihiro Suzuki
    Shigemi Matsumoto
    Takafumi Nishimura
    Yukiko Mori
    Toshihiko Masui
    Yoshiya Kawaguchi
    Kazuhiro Yanagihara
    Shujiro Yazumi
    Tsutomu Chiba
    Sushovan Guha
    Bharat B. Aggarwal
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 157 - 164
  • [45] A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer
    Yi, Jun Ho
    Lee, Jeeyun
    Park, Se Hoon
    Lee, Kyu Taek
    Lee, Jong Kyun
    Lee, Kwang Hyuck
    Choi, Dong Wook
    Choi, Seong-Ho
    Heo, Jin-Seok
    Lim, Do Hoon
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Keunchil
    Park, Joon Oh
    ONCOLOGY, 2011, 80 (3-4) : 175 - 180
  • [46] The efficacy of capecitabine plus oxaliplatin combination chemotherapy for advanced pancreatic cancer after failed with gemcitabine-based therapy
    Ryu, Ji Kon
    Jung, Kwang Hyun
    Kim, Yong-Tae
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 239 - 239
  • [47] Gemcitabine-based induction chemotherapy and concurrent with radiation in advanced head and neck cancer
    Doaa Ali Sharaf El Deen
    Eman Abd Elkareem Toson
    Shawky Mahmoud El Morsy
    Medical Oncology, 2012, 29 : 3367 - 3373
  • [48] Gemcitabine-based induction chemotherapy and concurrent with radiation in advanced head and neck cancer
    El Deen, Doaa Ali Sharaf
    Toson, Eman Abd Elkareem
    El Morsy, Shawky Mahmoud
    MEDICAL ONCOLOGY, 2012, 29 (05) : 3367 - 3373
  • [49] Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment
    Matsubara, Junichi
    Ono, Masaya
    Honda, Kazufumi
    Negishi, Ayako
    Ueno, Hideki
    Okusaka, Takuji
    Furuse, Junji
    Furuta, Koh
    Sugiyama, Emiko
    Saito, Yoshiro
    Kaniwa, Nahoko
    Sawada, Junichi
    Shoji, Ayako
    Sakuma, Tomohiro
    Chiba, Tsutomu
    Saijo, Nagahiro
    Hirohashi, Setsuo
    Yamada, Tesshi
    MOLECULAR & CELLULAR PROTEOMICS, 2010, 9 (04) : 695 - 704
  • [50] Comparing gemcitabine-based combination chemotherapy with gemcitabine alone in inoperable pancreatic cancer: A meta-analysis.
    Liang, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 335S - 335S
12345